A method of treating a neurological disease due to altered transmission of brain neurotransmitters

 

(57) Abstract:

The invention relates to medicine, in particular, neurology, and can be used to treat Parkinson's disease, atherosclerotic encephalopathy with intellectual disabilities and memory, functional pain syndromes of the face and oral cavity. The method includes conducting electric stimulation to the tissue of the brain daily for 10 days with prior sedation of the body through intravenous metacin in the amount of 0.5-1.0 ml and short mononarkoz with respiratory support, the introduction of drugs for diplegia as ditilina the rate of 0.3-0.5 mg/kg weight of the patient and artificial ventilation of the lungs, and the stimulation produced by bilateral or monopolar electrodes on a patient's head with an electric current of 850 mA with a frequency of 27-40 Hz for 0.1 to 1.0 seconds with gentle set the amplitude of the pulses, after which carry out control and monitoring of the patient. The method is characterized by the fact that before each session electric stimulation exercise pharmacological induction of these neurotransmitters. The invention provides an optimal combination of treatment of patients. 1 C.p. f-crystals.

The vast number of diseases of the Central nervous system (CNS) due to altered transmission of neurotransmitters in different brain regions - their deficiency, excess or violation of the relationships between different groups of these biologically active substances. In the treatment of diseases of the Central nervous system caused by such breaches in the system of Central neuronal connections, use of electroconvulsive therapy with advanced introduction (depending on the disease) drugs, either stimulating or inhibiting specific neurotransmitters. So, when Parkinson's disease, which is caused by a deficiency of dopamine in subcortical sites before ECT treatment applied amantadine stimulating secretion of dopamine from intact dopaminergic neurons in the subcortical ganglia, with atherosclerotic encephalopathy accompanied by a deficiency of acetylcholine - cholinomimetic amiridin, when trigeminal neuralgia - GABA-ergicheskie the drug sodium oxybutyrate.

There is a method of treatment of neurological diseases, including vnutri therapy with a subsequent reduction in pay and a daily dose of drugs (see RF patent 2163492, class a 61 N 5/067, publ. 1999).

Also known is a method of treatment of ischemic heart disease, including General Wellness events, conservative medical therapy and laser therapy (see RF patent 2174023, class a 61 N 5/067, orabl.2001).

The closest known by its technical essence and the achieved result is selected as a prototype method for the treatment of neurological disease due to altered transmission of brain neurotransmitters, including pretreatment of the body through intravenous metacin in the amount of 0.5-1.0 ml and short mononarkoz with respiratory support, the introduction of drugs to diplegia as ditilina the rate of 0.3-0.5 mg/kg of patient's weight and ventilation of lungs when this stimulation is produced daily for 10 days through bilateral or monopolar electrodes on a patient's head with an electric current of 850 mA with a frequency of 27-40 Hz for 0.1 to 1.0 seconds with gentle set the amplitude of the pulses, after which carry out control and monitoring of the patient (Nelson A. I. a Practical guide to electroconvulsive therapy, Moscow, 1995, S. 50-52).

The present invention is to provide the optimal combination of complex therapeutic treatment of patients, based on an appropriate selection of basic and additional therapeutic effects, which implement their action in the body regardless of how the simultaneous application of those or other complex means for treating a particular patient.

This result is achieved in that in the method of treatment of neurological disease due to altered transmission of brain neurotransmitters, including pretreatment of the body through intravenous metacin in the amount of 0.5-1.0 ml and short mononarkoz with respiratory support, the introduction of drugs to diplegia as ditilina the rate of 0.3-0.5 mg/kg of patient's weight and ventilation of lungs when this stimulation is produced daily for 10 days through bilateral or monopolar electrodes on a patient's head with an electric current of 850 mA with a frequency of 27 - 40 Hz for 0.1 to 1.0 seconds with gentle set the amplitude of the pulses, after which carry out control and monitoring of the patient, before each session of the electric stimulation of Ossiach drugs this short mononarkoz carried out using Diprivan, ketamine or geksenala.

The stated set of essential features is a direct causal link to the achieved result.

A comparison of the claimed technical solution with the prototype allowed us to establish compliance with a criterion of "novelty", as it is not known from the prior art.

The proposed method is industrially applicable existing technical facilities and meets the criterion of "inventive step", because it is not obvious from the prior art, while the latter does not identify any transformations, characterized by distinctive features of the prototype substantial evidence on the achievement of the technical result.

Thus, the proposed technical solution meets the conditions of patentability of an invention.

Other known technical solutions for a similar purpose with such significant signs the applicant is not found.

The proposed method is as follows.

The stages of the proposed modification electr is certain neurotransmitters in the brain.

2. Premedication body - metacin 0.5-1.0 ml intravenous.

3. Reingestion, short, shallow mononarkoz - Diprivan, ketamine, geksenal.

4. Introduction preparations for diplegia - ditilin 0.3-0.5 mg/kg weight of the patient.

5. Artificial ventilation of the lungs (respiratory support starts immediately after the introduction of the patient in the anaesthetic).

6. Electric daily for 10 days, bilateral monopolar or imposition of electrodes on a patient's head, the current 850 mA with a frequency of 27-40 Hz for 0.1 to 1.0 seconds, the rhythm of the pulse - rare with gentle set amplitude.

7. Control and monitoring of the patient after the procedure (30 minutes).

The proposed method is illustrated by the following examples.

Example 1. Patient S. , 83 years, with rigid-akinetic form of parkinsonism, takes Naka (levadopa 0.25 g, carbidopa 25 mg) 3 tablets per day for 7 years. In the first six years was quite a good effect, in the last year appeared dyskinesia, motor fluctuations, increasing doses of Nacom led to severe orthostatic hypotension and nausea. On a scale Hyun and Yar - stage 4 disease (needed constant assistance in e is tadina (50 mg) resulted in statistically significant reduction of muscle stiffness and moderate reduction of tremor during dose reduction of Nacom to 2 tablets per day, while the condition of the patient on a scale Hyun-Yar corresponded to 3 points (periodic help strangers in obydennoi life). The follow-up within six months. Significant changes there.

Example 2. Patient N., 72 years. Atherosclerotic encephalopathy with intellectual disability disorders. In the last three years, growing labourie, crying, lethargy, memory loss on forthcoming events. Treatment acetabulum, piracetam, b vitamins, vascular drugs trental, ginkobiloba has not led to any significant improvement. The patient needs constant care of relatives. In neurological status - symptoms of oral automatism. Test for short-term auditory-verbal memory ("10 words" by A. R. Luria) to 4.2. Conducted 10 sessions of ECT with prior to oral administration of 40 mg of Americana an hour before each session. The condition has improved significantly, although the symptoms of oral automatism remained unchanged. Test "10 words" - 6,0 playable words. Performs a simple everyday things. In the care of relatives is not needed.

Example 3. Patient K., 46 years old. Glossalgia for two years without any significant improvement from Oren language and others). Due to pain in the tongue stopped working engineer. In the status - constant burning pain in the front 2/3 of the tongue, xerostomia, is a symptom of a "mirror" symptom "food dominants" depressive mood. Conducted 6 sessions of ECT with prior intravenous sodium oxybutyrate 10 minutes before the session. A very good result remained minor discomfort in the language, fully regressed xerostomia, disappeared symptom of the "mirror" and "food dominants". Returned to the previous work. The follow-up period for 8 months - minor periodic burning in the tip of the tongue after household troubles.

The proposed method confirms the clinical efficacy of use in the treatment of Parkinson's disease, parkinsonism and other extrapyramidal hyperkinetic disorders, trigeminal neuralgia, chronic pain syndromes.

1. A method of treating a neurological disease due to altered transmission of brain neurotransmitters, including electric stimulation to the tissue of the brain daily for 10 days with prior sedation of the body through intravenous metacin in the amount of 0.5-1.0 ml is at the rate of 0.3-0.5 mg/kg weight of the patient and artificial ventilation of the lungs, when this stimulation is produced by bilateral or monopolar electrodes on a patient's head with an electric current of 850 mA with a frequency of 27-40 Hz for 0.1 to 1.0 with a gentle set of pulse amplitude, followed by the control and observation of the patient, characterized in that before each session electric stimulation exercise pharmacological induction of these neurotransmitters.

2. The method according to p. 1, characterized in that the short-term mononarkoz carried out using Diprivan, ketamine or geksenala.

 

Same patents:
The invention relates to the correction of sensory, motor and/or cognitive failure using intracerebral transplantation of cells, and to cells and medicines for realization of the specified transplant
The invention relates to medicine, namely, neurology, and can be used as a method of treatment of multiple sclerosis

The invention relates to medicine, specifically to combinations of nucleoside reverse absorption of 5-HT and selective antagonist or partial agonist h5-HT1Bthe formula I used for the treatment of diseases mediated 5-hydroxytryptamine, such as depression, anxiety and OCD

The invention relates to medicine, namely to Pediatrics, and is intended for the treatment of bedwetting in children and adolescents

The invention relates to medical technology, and is intended to stimulate biological processes by influencing the electric current through the skin surface
The invention relates to medicine and can find application in the treatment of Central autonomic disorders

The invention relates to medicine and veterinary medicine and can be used for reflexology and local UV irradiation of the surface of the body of humans and animals

The invention relates to medical equipment, in particular electrotherapy, and can be used in physiotherapy for the effects of sinusoidal modulated currents in deep tissue via the reflex zones in the treatment of diseases of internal organs
The invention relates to medicine, physical therapy, and can be used to treat patients with climacteric syndrome

The invention relates to medical equipment, namely to physiotherapeutic devices designed for conducting exercises of the hands, massage and electrotherapy palms and Palmar surfaces of the fingers and subcutaneous tissues, including the impact on biologically active points
The invention relates to medicine, namely to dermatology, physiotherapy, plastic surgery, and is intended for rejuvenation and healing of the skin of the head and neck of a person

The invention relates to medicine and can be used for the treatment of periodontal disease and the mucous membranes of the oral cavity, in particular stomatitis
The invention relates to medicine, neurology, and can be used for the treatment of post-stroke paralysis
The invention relates to medicine, namely to psychotherapy and acupuncture
Up!